Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01338
|
|||||
Drug Name |
Metampicillin
|
|||||
Synonyms |
(2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-(methylideneamino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(2R)-2-(methylideneamino)-2-phenylacetamido]penicillanic acid; Blomopen; Bonopen; CHEBI:52060; Celinmicina; Elatocilline; G0H6U7VSTK; METHAMPICILLIN; Magnipen; Metampicilina; Metampicillina; Metampicilline; Metampicillinum; Micinovo; Pangocilin; Probiotic; Relyothenate; Ruticina; Rutizina; Sedomycin; Suvipen; UNII-G0H6U7VSTK; Viderpen; Viderpin; Vioplex; metampicillin; metampilene
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Preclinical | [1] | |||
Therapeutic Class |
Anti-Bacterial Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C17H19N3O4S
|
|||||
Canonical SMILES |
CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N=C)C(=O)O)C
|
|||||
InChI |
InChI=1S/C17H19N3O4S/c1-17(2)12(16(23)24)20-14(22)11(15(20)25-17)19-13(21)10(18-3)9-7-5-4-6-8-9/h4-8,10-12,15H,3H2,1-2H3,(H,19,21)(H,23,24)/t10-,11-,12+,15-/m1/s1
|
|||||
InChIKey |
FZECHKJQHUVANE-MCYUEQNJSA-N
|
|||||
CAS Number |
CAS 6489-97-0
|
|||||
Pharmaceutical Properties | Molecular Weight | 361.4 | Topological Polar Surface Area | 124 | ||
Heavy Atom Count | 25 | Rotatable Bond Count | 5 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
3
|
|||||
PubChem CID | ||||||
ChEBI ID |
CHEBI:52060
|
|||||
DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [2] | ||
References | ||||||
1 | G-SRS database: METAMPICILLIN | |||||
2 | Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.